Moving forward with Takeda's live chimeric tetravalent dengue vaccine
Several decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four dengue serotypes (DENV-1–4) for people of all ages. In light of the rapidly rising incidence of dengue virus infection, now estimated to affect about 100...
Saved in:
Main Author: | |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2017
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/83617 http://hdl.handle.net/10220/42732 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-83617 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-836172020-11-01T05:21:04Z Moving forward with Takeda's live chimeric tetravalent dengue vaccine Wilder-Smith, Annelies Lee Kong Chian School of Medicine (LKCMedicine) Dengue Vaccine Several decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four dengue serotypes (DENV-1–4) for people of all ages. In light of the rapidly rising incidence of dengue virus infection, now estimated to affect about 100 million individuals per year,1 the approval of the first dengue vaccine developed by Sanofi Pasteur (CYD-TDV) was a welcome step forward.2 However, the first vaccine does not present a simple solution. Accepted version 2017-06-20T04:31:58Z 2019-12-06T15:26:50Z 2017-06-20T04:31:58Z 2019-12-06T15:26:50Z 2017 Journal Article Wilder-Smith, A. (2017). Moving forward with Takeda's live chimeric tetravalent dengue vaccine. The Lancet Infectious Diseases, 17(6), 566-568. 1473-3099 https://hdl.handle.net/10356/83617 http://hdl.handle.net/10220/42732 10.1016/S1473-3099(17)30165-2 en The Lancet Infectious Diseases © 2017 Elsevier Ltd. This is the author created version of a work that has been peer reviewed and accepted for publication by The Lancet Infectious Diseases, Elsevier Ltd. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1016/S1473-3099(17)30165-2]. 4 p. application/pdf |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
Dengue Vaccine |
spellingShingle |
Dengue Vaccine Wilder-Smith, Annelies Moving forward with Takeda's live chimeric tetravalent dengue vaccine |
description |
Several decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four dengue serotypes (DENV-1–4) for people of all ages. In light of the rapidly rising incidence of dengue virus infection, now estimated to affect about 100 million individuals per year,1 the approval of the first dengue vaccine developed by Sanofi Pasteur (CYD-TDV) was a welcome step forward.2 However, the first vaccine does not present a simple solution. |
author2 |
Lee Kong Chian School of Medicine (LKCMedicine) |
author_facet |
Lee Kong Chian School of Medicine (LKCMedicine) Wilder-Smith, Annelies |
format |
Article |
author |
Wilder-Smith, Annelies |
author_sort |
Wilder-Smith, Annelies |
title |
Moving forward with Takeda's live chimeric tetravalent dengue vaccine |
title_short |
Moving forward with Takeda's live chimeric tetravalent dengue vaccine |
title_full |
Moving forward with Takeda's live chimeric tetravalent dengue vaccine |
title_fullStr |
Moving forward with Takeda's live chimeric tetravalent dengue vaccine |
title_full_unstemmed |
Moving forward with Takeda's live chimeric tetravalent dengue vaccine |
title_sort |
moving forward with takeda's live chimeric tetravalent dengue vaccine |
publishDate |
2017 |
url |
https://hdl.handle.net/10356/83617 http://hdl.handle.net/10220/42732 |
_version_ |
1683493779057672192 |